These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18791333)

  • 61. National plans and strategies on rare diseases in Europe.
    Taruscio D; Vittozzi L; Stefanov R
    Adv Exp Med Biol; 2010; 686():475-91. PubMed ID: 20824461
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmaceuticals. Adopt an orphan.
    Karr A
    Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
    [No Abstract]   [Full Text] [Related]  

  • 65. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
    Montanaro N; Bonaldo G; Motola D
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1057-1063. PubMed ID: 33501508
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [RARE DISEASES DTC: DIAGNOSIS, TREATMENT AND CARE].
    Mendlovic J; Barash H; Yardeni H; Banet-Levi Y; Yonath H; Raas-Rothschild A
    Harefuah; 2016 Apr; 155(4):241-4, 253. PubMed ID: 27323543
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What is wrong with orphan drug policies? Suggestions for ways forward.
    Kanavos P; Nicod E
    Value Health; 2012 Dec; 15(8):1182-4. PubMed ID: 23244822
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A proposal to improve the supply of orphan drugs.
    Minghetti PM; Giudici EM; Montanari L
    Pharmacol Res; 2000 Jul; 42(1):33-7. PubMed ID: 10860632
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluating and improving orphan drug regulations in Europe: a Delphi policy study.
    Picavet E; Cassiman D; Simoens S
    Health Policy; 2012 Nov; 108(1):1-9. PubMed ID: 22989856
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Why we should care about ultra-rare disease.
    Harari S
    Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The need for worldwide policy and action plans for rare diseases.
    Forman J; Taruscio D; Llera VA; Barrera LA; Coté TR; Edfjäll C; Gavhed D; Haffner ME; Nishimura Y; Posada M; Tambuyzer E; Groft SC; Henter JI;
    Acta Paediatr; 2012 Aug; 101(8):805-7. PubMed ID: 22519914
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
    Polsinelli B; Tsigkos S; Naumann-Winter F; Mariz S; Sepodes B
    Orphanet J Rare Dis; 2017 Jan; 12(1):17. PubMed ID: 28109318
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Hungarian national plan and strategy for rare diseases].
    Kosztolányi G
    Orv Hetil; 2014 Mar; 155(9):325-8. PubMed ID: 24566695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States.
    Ivaskiene T; Mauricas M; Ivaska J
    Curr Stem Cell Res Ther; 2017; 12(1):45-51. PubMed ID: 27412678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.